Selinexor with standard therapies for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has returned or is no longer responding to treatment.
- You have measurable signs of myeloma in your blood or urine (like M-protein or free light chains).
- You are able to walk and take care of yourself (performance status score of 0 to 2).
- Your liver and kidney function tests meet specific levels depending on the drug combination you might receive.
- If you are a woman who can become pregnant, you must have a negative pregnancy test and agree to use effective birth control during and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
This trial tests if the drug selinexor can help prevent multiple myeloma from coming back after CAR-T cell therapy. It is for people with high-risk or persistent myeloma who have already received a specific CAR-T treatment called Carvykti.
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
This Phase 2 trial studies a treatment called SVRd in people newly diagnosed with multiple myeloma that has spread to areas outside the bone (called extramedullary disease). It aims to see how well the treatment works and whether it is safe for this specific group.
This study tests a new drug called TQB2934 for patients whose multiple myeloma (a blood cancer) has returned or stopped responding to previous treatments. The goal is to see if this injection can help control the disease.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.